Half-life extension

Most half-life extension strategies target an increase in the hydrodynamic radius of small protein drugs to protect rapid clearance from circulation through the renal route. Boehringer Ingelheim has substantial experience in PEGylation (adding polyethylene glycol) and HSA-fusions (human serum albumin fusion expressed in Pichia pastoris) of antibody derivatives and scaffold molecules. Furthermore, Boehringer Ingelheim BioXcellence™ and Fresenius Kabi successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabi’s HESylation® Technology.

Contact Us

Boehringer Ingelheim BioXcellence - Contact Us

Do you have any inquiries, questions or comments? Please get in touch with us.